Notes / Company

Gufic Biosciences Ltd.

GUFICBIO BSE 509079 ISIN INE742B01025 Pharmaceuticals

Fundamentals

Market cap: ₹3,627 cr
P/E: 56.48×
ROE: 11.59%
Debt / equity: 0.52
Div yield: 0.03%
52-week range: 268.00 — 407.85

Research on Tijori Finance

Company snapshot

Gufic Biosciences Ltd.

Pharmaceuticals

₹3,612 cr

P/E 57.19×

Latest quarter · Mar 2026

Sales₹252 cr

Net profit₹22 cr

Op. margin+18.8%

EPS₹2.18

Strength & growth

Debt / equity0.52×

Current ratio1.61×

Sales CAGR+16.6%

EPS CAGR+21.3%

The timeline — 1 note on Gufic Biosciences Ltd.

June 2026

05 Jun 26 · 6:14 PM IST Brief

Brief · Earnings · Small cap

Gufic posts best-ever quarter, profit doubles on Indore breakeven

Record ₹252 cr revenue and ₹20.5 cr net profit. The Indore plant's breakeven at 30% use is the operational driver behind the FY27 guidance.

Verify on exchange BSE filings for GUFICBIO NSE filings for GUFICBIO Tijori Finance company page